Replies to post #200522 on Amarin Corp Plc (AMRN)

[MedResCollab]

Massulo, I’m afraid you’ve missed the point completely. The only rationale given by that physician to take 2 g/d Vascepa for at-risk patients is because 4 g/d is currently too expensive. And, presumably, because telling people to turn to third-party tested supplements that show exceptional TOTOX scores and accurate or better levels of stated API (EPA) to get their 4 g/d of EPA would not benefit the company they are invested in. That is deplorable.

Regards,
-MRC

[docnj]

massulo52, i agree physicans can write for lower doses. certainly there are multiple doses of most blood pressure medications and many other types of medications. often doses need to be titrated as each patient is an individual.
that being said, the data clearly shows benefit at 2gms bid, with no proven data for any other dosing

if a physician uses a lower dose, say due to cost (or side effects), and then monitors the patient and finds a beneficial effect, that would seem resonable. however, the beneficial effect is in the surrogate marker, such as tg level etc.
this is part of the strength of V and why we want V used. you can give other fish oil products AND show a surrogate marker improvement, however, only V has a long term large subject outcome study looking at MACE.